Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies
- Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies
- Ahmed Mahammed Elkamhawy; 박정은; 조남철; 심태보; 배애님; 노은주
- CYP450; DDR1 kinase inhibitor; kinase panel; molecular docking; NCI panel
- Issue Date
- Journal of enzyme inhibition and medicinal chemistry
- VOL 게재예정, 게재예정
- Herein, we report compound KST9046, a new agent possessing quinazoline-urea scaffold.
Preliminary biological evaluation done by the National Cancer Institute (NCI), USA, showed a
great inhibitory effect of KST9046 over the 60 cell-line tumor panel. Accordingly, it was selected for a dose-response assay; a broad spectrum antiproliferative activity with GI50 ranging from 1.3 to 3.9 mM was exerted. To explore a potential kinase inhibitory effect, KST9046 was applied at a single dose of 10 mM against a kinase panel of 347 different enzymes representing
450% of the predicted human protein kinome. Interestingly, selective inhibition of 76% was observed on DDR1 kinase. Further, KST9046 showed an IC50 value of 4.38 mM for DDR1. A molecular docking model presented KST9046 as a potential type III inhibitor for DDR1 kinase with an allosteric mode of interaction, which may offer an explanation for its selectivity. As further investigation, CYP450 assay was carried out for KST9046, it showed a promising toxicity profile against four different isoforms. Based on these findings, KST9046 can be further evaluated as a promising safe new hit for the development of broad spectrum anticancer agents with a selectivity for DDR1 kinase.
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.